Mini and enhanced CRISPR activators for cancer therapies
We have successfully developed and demonstrated a breakthrough CRISPRa tool with promising implications for cancer genetic therapy. This innovation expands the range of available gene editing tools and further validates the immense potential of CRISPR-based approaches in precision medicine.
Authors
- Xiagu Zhu
- Meiyu Huang (ORCID: https://orcid.org/0000-0002-7513-1764)
- Zuping Zhou (ORCID: https://orcid.org/0000-0002-7543-4765)
- Anshu Li
- Keshan Wang (ORCID: https://orcid.org/0000-0002-4128-2214)
- Changhao Bi (ORCID: https://orcid.org/0000-0002-1940-8511)
- Chao Yang (ORCID: https://orcid.org/0000-0003-3422-2763)
- Xueli Zhang (ORCID: https://orcid.org/0000-0002-8660-4037)
Institutions
- Union Hospital (HK)
- Tianjin University of Science and Technology (CN)
- Chinese Academy of Sciences (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Guangxi Normal University (CN)
- Tianjin Institute of Industrial Biotechnology (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2024-11-03
- DOI
- https://doi.org/10.1016/j.jare.2024.10.027
- Citations
- 1
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- National Natural Science Foundation of China
- Government of Jiangxi Province
- Natural Science Foundation of Tianjin City
- National Key Research and Development Program of China